Data on the use of the tumor necrosis factor inhibitor (TNFi) etanercept (ETN) in JPsA have been provided by the CLIPPER study, which demonstrated the effectiveness and safety of ETN in a JIA cohort including patients with extended oligoarticular JIA, ERA, and JPsA [40,41,42]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.